Quantcast

Latest advanced cancer Stories

2014-06-10 08:30:04

--Study in Nature Genetics Used PGDx Exome Analysis to Identify Previously Unknown Mutation with Potential as New Drug Target for Lethal Childhood Brain Cancer-- BALTIMORE, June 10, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its exome analysis services played a central role in several cancer studies recently published in leading scientific journals. PGDx's exome analysis...

2014-04-02 08:32:57

--First-in-Class CLIA Assay for Detection of Tumor-Specific Gene Amplifications Using Circulating Cell-Free DNA-- BALTIMORE, April 2, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analyses, today announced the launch of its METDetect(TM) Assay for the detection of MET gene amplifications in the circulation of cancer patients. Amplifications and other structural changes of the MET cancer gene have been associated with resistance to...

2014-02-19 16:24:15

--New Publication in Science Translational Medicine Confirms Utility of Cell-Free Circulating Tumor DNA (ctDNA) for Cancer Drug Development and Diagnosis-- BALTIMORE, Md., Feb. 19, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published today in the journal Science Translational Medicine. The study, "Detection of...

2014-01-18 12:20:20

SAN FRANCISCO, Jan. 18, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with 5-fluorouracil (5-FU)/Leucovorin (LV) in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated...

2013-01-07 14:54:23

Blueprint could help guide treatment for patients who have exhausted all other options Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, is now offering patients with advanced cancer a cutting-edge clinical test that will provide them with a unique blueprint of their cancer genes. The new clinical test, known as CancerCode-45TM, evaluates an individual's tumor for genetic alterations in a select group of 45 genes and gives physicians the...

2012-02-14 11:40:16

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related